# Scribe Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Scribe Therapeutics, Inc.). ## Overview Scribe Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing precision-engineered CRISPR genetic medicines. Its wholly owned pipeline focuses on cardiometabolic diseases, including atherosclerotic cardiovascular disease, while collaborations with Eli Lilly and Sanofi apply its ELXR and XE technologies to additional therapeutic areas. ## Products & services • Precision-engineered CRISPR genetic medicines • ELXR gene-editing technology platform • XE gene-editing technology platform • STX-1150 cardiometabolic program • Partnered research and development programs - **Wholly owned therapeutic pipeline** (0%) — Genetic medicine programs targeting cardiometabolic diseases such as ASCVD. - **CRISPR technology platforms** (35%) — ELXR and XE platforms designed to support precision gene-editing applications. - **Collaborative research programs** (65%) — Partner-funded development programs with Eli Lilly, Sanofi, and other potential collaborators. - Precision-engineered CRISPR genetic medicines - ELXR gene-editing technology platform - XE gene-editing technology platform - STX-1150 cardiometabolic program - Partnered research and development programs ## Customers Scribe's current commercial counterparties are biopharmaceutical collaborators, including Eli Lilly and Sanofi, which license or fund applications of its gene-editing technologies in selected therapeutic areas. These partners provide research funding, upfront payments, milestone opportunities, and potential royalties while contributing development and commercialization capabilities. Future end-market customers would include healthcare providers, payors, and patients if Scribe's product candidates receive regulatory approval. - **Biopharmaceutical collaborators** (primary) — License Scribe's CRISPR platforms and fund therapeutic development in selected disease areas. - **Healthcare providers** (secondary) — Would administer or prescribe approved genetic medicines for cardiometabolic and other diseases. - **Commercial and government payors** (secondary) — Would reimburse approved therapies and influence patient access through coverage decisions. - **Patients** (secondary) — Would receive durable, potentially single-administration treatments for serious diseases. - Biopharmaceutical partners license technology and fund development - Eli Lilly and Sanofi support programs outside cardiometabolic disease - Healthcare providers could use approved genetic medicines - Payors determine coverage and reimbursement for future products - Patients would receive therapies for targeted genetic diseases ## Geography Scribe Therapeutics is headquartered and organized in the United States, where its research, corporate, clinical-development, and public-company activities are managed. The company does not disclose country-level revenue or a regional revenue mix in the provided materials. Its collaborations and future clinical programs may require international regulatory, trial, manufacturing, and commercialization activities. - United States is the company's disclosed home market - Research and corporate operations are U.S.-based - Clinical development may involve international trial sites - Collaborators can extend programs beyond the United States - Future commercialization would require regional market access ## Strategy Scribe's strategy is to advance its wholly owned cardiometabolic pipeline while using its CRISPR platforms in collaborations that broaden therapeutic reach and provide non-dilutive funding. Near-term development priorities include progressing STX-1150, advancing additional preclinical and clinical programs, and building manufacturing, clinical, intellectual-property, and public-company capabilities. Collaborations with Eli Lilly and Sanofi are intended to validate platform versatility and share development and commercialization requirements. - **Advance the cardiometabolic pipeline** (short-term) — Clinical progress is required to convert the technology platform into proprietary medicines. - **Expand platform partnerships** (medium-term) — Collaborations extend applications of ELXR and XE while sharing development and commercialization resources. - **Build development and commercialization infrastructure** (medium-term) — Manufacturing, clinical, regulatory, and commercial capabilities are necessary for eventual product approval and launch. - Advance STX-1150 through clinical development - Develop durable genetic medicines for cardiometabolic disease - Apply ELXR and XE platforms across partner programs - Use collaborations to fund research and reduce dilution - Build clinical, manufacturing, and operating capabilities - Expand intellectual-property protection around the platforms ## Risks Scribe remains dependent on successful research, preclinical and clinical development, regulatory approval, and eventual market access because it has no approved products or product sales. Its collaboration-based revenue model exposes it to partner decisions on funding, trial execution, and commercialization, while the capital-intensive pipeline creates ongoing financing and dilution risk. Competition from established gene-editing and pharmaceutical companies, intellectual-property challenges, manufacturing constraints, and difficulty recruiting specialized personnel could delay or prevent commercialization. - **Clinical-stage development failure** [critical] — Safety, efficacy, enrollment, manufacturing, or regulatory problems could prevent approval of product candidates. - **Funding and dilution risk** [critical] — The company has significant operating losses and negative operating cash flow while development requires substantial capital. - **Collaboration dependence** [high] — Partners may delay, reduce, or terminate programs and control resources dedicated to development and commercialization. - **Competitive pressure** [high] — Large pharmaceutical and biotechnology companies may have greater development, regulatory, manufacturing, and marketing resources. - **Market access and reimbursement** [high] — Approved therapies may face restrictive coverage, inadequate reimbursement, or limited provider and patient adoption. - **Key personnel dependence** [medium] — Loss of technical, scientific, or management personnel could delay programs and weaken execution. - No approved products means commercialization remains unproven - Clinical or preclinical failures could eliminate programs - Additional funding may be needed before product revenue - Partners control resources and timing in collaboration programs - Established competitors have greater capital and expertise - Specialized personnel and manufacturing capacity may be scarce ## Accounting Collaboration revenue is recognized from upfront, milestone, contingent, full-time-equivalent, and reimbursed out-of-pocket payments under collaboration and license agreements, making reported revenue dependent on contract terms and milestone probability assessments. The fair value of the Eli Lilly convertible note creates period-to-period earnings volatility through interest expense and valuation changes. Scribe also carries substantial judgment around deferred tax assets, which are subject to a full valuation allowance because future realization remains uncertain. - **Collaboration and license revenue recognition** — Revenue can fluctuate substantially between reporting periods without corresponding product sales. - **Milestone probability assessment** — Clinical and regulatory progress can change the timing of reported collaboration revenue. - **Convertible note fair value** — Changes in valuation create non-operating earnings volatility. - **Research and development cost recognition** — Timing of vendor delivery and clinical services affects reported operating expenses. - **Deferred tax asset valuation allowance** — Tax benefits are generally not recognized until future taxable income becomes more probable. - Collaboration revenue timing depends on performance obligations - Milestones are recognized only when reversal risk is remote - Partner reimbursements and upfront payments can cause volatility - Lilly convertible note fair value affects reported earnings - R&D costs are expensed as incurred - Deferred tax assets have a full valuation allowance --- *Last updated: 2026-09-24T12:34:49.570075+00:00*